glp-1 receptor agonists as Treatments for Type 2 Diabetes Comparing Ozempic, Wegovy and Other
Description
R.DiazR.LakshmananM.PaisP.et al (2019)
EMA: While the FDA granted Wegovy an additional indication for CV risk reduction, the EMA did not deem this necessary and only added SELECT data to its label
Standard semaglutide or tirzepatide pens are available with a fixed strength
Funding There is no funding associated with this project
JCEM 2024 Online Supplement
89 In vitro, high glucose increased the expression of inflammasome recombinant NLR Family, pyrin domain containing protein 3 (NLRP3) markers in hippocampal cells
